Abstract:OBJECTIVE To investigate the efficacy and side effects of mycophenolate mofetil (MMF) in the treatment of diffuse proliferative lupus nephritis( DPLN). METHODS 75 patients [13 male,62 female; age (31.0 +/- 10.1)y] with biopsy-proven active DPLN from nine hospitals in China from Jan. 1999 to Jan. 2000 were enrolled in this study, of whom 26 patients were refractory to conventional treatment of steroids and cyclophosphamide. 21 patients presented with relapses and 28 patients were newly diagnosed. All the patients were treated with a combined regimen of MMF and steroids. Patients who had severe active renal lesions were initially given intravenous methylprednisolone followed by oral prednisone. The initial dosage of MMF was 0.5 approximately 2.0 g/d and the administrati on maintained at least 6 months. 38 patients had repeat renal biopsy after treatment. SLE disease activity (SLE-DAI) score, renal active index (AI),chronic index(CI) and density of immunoglobulins, complement deposition was assessed before and after MMF treatment. RESULTS The mean starting dosage of MMF was (1.26 +/- 0.30) g/d, it was reduced to (1.21 +/- 0.30) g/d and (0.95 +/- 0.33) g/d at the end of the 3(rd) and 6(th) month respectively. The post-treatment Hb level increased from (92 +/- 21) g/L to (112 +/- 28) g/L(3 mo) and (116 +/- 21) g/L(6 mo), while proteinuria decreased from (4.24 +/- 2.66) g/d to (2.18 +/- 3.75) g/d (3 mos, P < 0.05) and (1.54 +/- 1.60) g/d( 6 mos,P < 0.01). Renal function impairment present in some of the patients also showed marked improvement. The proportion of patients with positive A-dsDNA antibody and hypocomplementemia was significantly reduced after 6 months of MMF treatment. SLE-DAI score in this group of patients decreased from (16.9 +/- 6.7) to (8.1 +/- 4.8) (P < 0.01) by the end of 3 months. Repeat renal biopsy in 38 patients 3 approximately 6 months after the treatment showed a significant decrement of AI ( 13.30 +/- 5.51) vs (3.38 +/- 1.98),P < 0.01, and an increment of CI (1.62 +/- 1.48) vs (2.62 +/- 1.85), P > 0.05. Immunoglobulins and complement deposition scores decreased from (9.39 +/- 3.51) to(6.71 +/- 3.16 ),P < 0.05. During the study period, 12 episodes of infection (16.0%) were recorded including pneumonia(2.7%), herpes zoster(8.0 %), urinary tract infection(2.7%), and tuberculosis(2.7%). Other side effects included gastrointestinal symptoms (10.7%), hirsutism(6.7%), leukocytopenia (1.3%) and transient elevation of SGPT(2.7%). CONCLUSION MMF in a dosage of 0.5 approximately 2.0 g/d combined with steroids is effective to control the lupus activity of DPLN and well tolerated by the patients.

Evaluation of the efficacy of mycophenolate mofetil treatment in lupus nephritis

Clinical observations of mycophenolate mofetil therapy in refractory primary nephrotic syndrome.

Three-year Follow-up Study of Lupus Nephritis Treated with Mycophenolate Mofetii

Efficacy and long-term prognosis of mycophenolate mofetil treatment on patients with proliferative lupus nephritis

Combined Therapy of Mycophenolate Mofetil and Prednisone for Refractory Lupus Nephritis

Mycophenolate Mofetil Treatment for Diffuse Proliferative Lupus Nephritis: a Multicenter Clinical Trial in China.

Mycophenolate mofetil (MMF) used for treating type Ⅳ lupus nephritis and literature review

Mycophenolate Mofetil in the Treatment of Primary Nephrotic Syndrome

Mycophenolate Mofetil for Proliferative Lupus Nephritis: A Systematic Review

Clinical study of mycophenolate mofetil therapy versus intermittent cyclophosphamide pulse treatment in lupus nephritis

Efficiency and Safety of Mycophenolate Mofetil Dispersible Tablets in Patients with Proliferative Lupus Nephritis: an Open-Labeled Pilot Study

The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schönlein purpura nephritis.

Mycophenolate Mofetil in Induction and Maintenance Therapy of Severe Lupus Nephritis: a Meta-Analysis of Randomized Controlled Trials.

Mycophenolate mofetil in the treatment of Chinese patients with lupus nephritis A PRISMA-compliant meta-analysis

Combined treatment of small dose corticosteroids and mycophenolate mofetil for lupus nephritis

Mycophenolate Mofetil Versus Intravenous Pulse Cyclophosphamide for Class Ⅳ Plus Ⅴ Lupus Nephritis

Comparison of efficacy of continuous mycophenolate mofetil with sequential cyclophosphamide and tacrolimus as maintenance therapy for lupus nephritis

Treatment of Refractory Nephropathy in Children with Mycophenolate Mofetil

Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study.

Mycophenolate mofetil combined with low dose prednisone in the treatment for adults with minimal change nephrotic syndrome and concomitant HBsAg positive

A clinical study of mycophenolate mofetil combined with low-dose steroids in the management of pediatric systemic lupus erythematosus